Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Maqitong Capsule post-marketing study in stable coronary heart disease with angina
ChiCTR2300068203Phase 4Completed
- Sponsor
- Zhejiang Hospital
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fufang maqitong in coronary arteriosclerosis and angina pectoris, sponsored by Zhejiang Hospital. Primary endpoints: Physical examination at day 60, Vital signs at day 60 and 7 more. Started Dec 2022; status: completed.
02
Drugs
fufang maqitong
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on ChiCTR2300068203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068203.